Cidara Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, CDTX, Cidara Therapeutics Inc, priceseries

Cidara Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
0.67
Close
0.67
High
0.69
Low
0.65
Previous Close
0.69
Daily Price Gain
-0.02
YTD High
1.41
YTD High Date
Jan 3, 2022
YTD Low
0.63
YTD Low Date
Feb 24, 2022
YTD Price Change
-0.72
YTD Gain
-51.99%
52 Week High
3.08
52 Week High Date
Apr 5, 2021
52 Week Low
0.63
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-1.73
52 Week Gain
-72.20%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 20. 2017
6.95
Oct 6. 2017
7.71
12 Trading Days
10.94%
Link
LONG
May 22. 2018
4.90
Jun 7. 2018
5.43
11 Trading Days
10.91%
Link
LONG
Jan 2. 2019
2.70
Jan 3. 2019
2.94
1 Trading Days
8.83%
Link
LONG
Aug 27. 2019
1.50
Sep 17. 2019
2.06
14 Trading Days
37.54%
Link
LONG
Dec 23. 2019
2.54
Jan 10. 2020
3.30
12 Trading Days
30.10%
Link
LONG
Mar 23. 2020
2.21
May 1. 2020
2.69
28 Trading Days
21.79%
Link
LONG
May 18. 2020
3.20
Jun 5. 2020
3.49
13 Trading Days
9.12%
Link
LONG
Aug 7. 2020
3.90
Aug 12. 2020
4.12
3 Trading Days
5.64%
Link
LONG
Mar 8. 2021
2.40
Mar 17. 2021
2.58
7 Trading Days
7.42%
Link
LONG
Mar 31. 2021
2.66
Apr 5. 2021
2.87
2 Trading Days
7.89%
Link
LONG
Aug 18. 2021
1.78
Sep 7. 2021
2.07
13 Trading Days
16.36%
Link
Company Information
Stock Symbol
CDTX
Exchange
NasdaqGM
Company URL
http://www.cidara.com
Company Phone
858-752-6170
CEO
Jeffrey L. Stein
Headquarters
California
Business Address
6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001610618
About

Cidara Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of anti-infectives for the treatment of fungal infections. Is portfolio includes CD101 IV, CD101 Topical, and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Description

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious, invasive fungal infections. The company also develops CD201, a novel bispecific antimicrobial immunotherapy for the treatment of multidrug-resistant gram-negative bacterial infections, including those caused by pathogens harboring the mcr-1 plasmid. In addition, it develops a proprietary immunotherapy technology platform Cloudbreak, which is designed to create compounds that direct immune system to attack and eliminate bacterial, fungal or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading